Oncobiologics (NASDAQ:OTLK) versus Tango Therapeutics (NASDAQ:TNGX) Head-To-Head Review

Oncobiologics (NASDAQ:OTLK) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Institutional & Insider Ownership

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Oncobiologics and Tango Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	5	1	0	2.00
Tango Therapeutics	1	2	13	0	2.75

Oncobiologics currently has a consensus price target of $6.50, suggesting a potential upside of 367.63%. Tango Therapeutics has a consensus price target of $42.15, suggesting a potential upside of 47.60%. Given Oncobiologics’ higher probable upside, research analysts clearly believe Oncobiologics is more favorable than Tango Therapeutics.

Volatility & Risk

Oncobiologics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Earnings & Valuation

This table compares Oncobiologics and Tango Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35 million	152.99	-$62.42 million	($1.17)	-1.19
Tango Therapeutics	$62.38 million	66.23	-$101.59 million	($0.83)	-34.41

Oncobiologics has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Oncobiologics and Tango Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Tango Therapeutics	N/A	-41.54%	-33.44%

Summary

Tango Therapeutics beats Oncobiologics on 8 of the 13 factors compared between the two stocks.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.